Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformGlobeNewsWire • 03/19/24
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsGlobeNewsWire • 02/29/24
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDGlobeNewsWire • 02/20/24
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsGlobeNewsWire • 01/24/24
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptGlobeNewsWire • 11/28/23
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer ImmunotherapyGlobeNewsWire • 11/15/23
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan KhattakGlobeNewsWire • 11/06/23
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01GlobeNewsWire • 10/31/23
New and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be PresentedGlobeNewsWire • 10/26/23
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against GonorrheaGlobeNewsWire • 09/20/23
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical companyGlobeNewsWire • 09/18/23
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine DevelopmentGlobeNewsWire • 09/11/23